Revolution Medicines, Inc.
RVMD
株式のランク
#580
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
株価
$196.16
最終同期: 2026-10-20
時価総額
$42.04B
変化（1日）
7.69%
変化（1年）
266.72%
国
US
取引 Revolution Medicines, Inc. (RVMD)
カテゴリー
Healthcare
Revolution Medicines, Inc.（RVMD）のP/E比率
October 2026 時点のP/E比率 TTM -21.84
Revolution Medicines, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -21.84 です。2023 年末時点での P/E は -7.44 でした。
Revolution Medicines, Inc. の P/E 比率の履歴（2017 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -21.84 | 78.59% |
| 2024 | -12.23 | 64.40% |
| 2023 | -7.44 | -3.70% |
| 2022 | -7.72 | -21.16% |
| 2021 | -9.79 | -59.82% |
| 2020 | -24.38 | 10.23% |
| 2019 | -22.11 | -12.33% |
| 2018 | -25.22 | -25.51% |
| 2017 | -33.86 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -231.77% |
US
|
|
| -28.36 | 29.83% |
US
|
|
| -24.57 | 12.48% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -238.86% |
NL
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。